Paris NASH Meeting
July 9 & 10, 2020
Institut Pasteur
6th edition

Organized by
Arun Sanyal
Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

Lawrence Serfaty
Hôpital Hautepierre Hôpitaux Universitaires de Strasbourg, France

Scientific committee
Quentin Anstee
Pierre Bedossa
Laurent Castera
Jean-François Dufour
Scott Friedman
Fabio Marra
Philippe Mathurin
Veronica Miller
Manuel Romero-Gómez
Frank Tacke
Michael Trauner

With the partnership of
THURSDAY, JULY 9, 2020

08:00 - 08:30 am     CONFERENCE OPENING
08:30 - 08:35 am     Welcome remarks - Lawrence Serfaty (France)
08:35 - 08:45 am     Inauguration Address - Director Pasteur Institute

08:45 - 10:00 am     SESSION 1 • PUBLIC HEALTH AND POLICY
                      Chairs: Patrick Marcellin (France) and Arun Sanyal (USA)
                      A patients journey with NASH.
                      Eu patient
                      Primary care referral for NAFLD: the UK experience.
                      Emmanuel Tsochatzis (United Kingdom)
                      Generating real world evidence from efficacy to effectiveness.
                      Michael Fried (USA)
09:30 - 10:00 am     Discussion

10:00 - 10:30 am     COFFEE BREAK AND POSTERS

10:30 - 12:00 am     SESSION 2 • GENETIC AND METABOLIC DRIVERS OF DISEASE PROGRESSION
                      Chairs: Philippe Mathurin (France) and Lawrence Serfaty (France)
                      Gene-environment interactions in NASH.
                      Stefano Romeo (Sweden)
                      Metabolic flexibility is the key to the biology of NASH.
                      Mohammad Siddiqui (USA)
                      What can we learn from lipodystrophies about NASH.
                      Jocelyne Magré (France)
                      Pharmacogenomics for NASH: current state of the art.
                      Quentin Anstee (United Kingdom)

11:30 - 12:00 pm     Discussion
STATE OF THE ART LECTURE
Chair: Arun Sanyal (USA)
Bile acid-Microbiome interactions in the development of human disease.
TBC

LUNCH BREAKOUT SESSION - CASE BASED DISCUSSIONS
GROUP 1: Industry symposium
GROUP 2: How to integrate NASH assessment and management into the care of the patient with metabolic syndrome.
Laurent Castera (France) and Mary Rinella (USA)
GROUP 3: Management of obesity by targeting gut hormones
Luc Van Gaal (Belgium) and Bart Staels (France)

SESSION 3 • CLINICAL ASPECTS OF NAFLD
Chairs: Quentin Anstee (United Kingdom) and Fabio Marra (Italy)

02:30 - 02:45 pm Does NASH contribute to clinical course of patients after successful HCV therapy
Lawrence Serfaty (France)

02:45 - 03:00 pm Gender difference in NASH susceptibility
Philippe Mathurin (France)

03:00 - 03:15 pm When disease activity can be confused with DILI in the patient
Arie Regev (USA)

03:15 - 03:30 pm Modeling the risk of HCC in NAFLD
Jean-François Dufour (Switzerland)

03:30 - 04:00 pm Discussion

COFFEE BREAK AND POSTERS
04:30 - 06:00 pm  
**SESSION 4 • TECHNOLOGICAL INNOVATIONS IN NASH**
Chairs: Manuel Romero-Gómez (Spain) and Franck Tacke (Germany)

04:30 - 04:45 pm  
Pierre Bedossa (France)

04:45 - 05:00 pm  
Can iPSC derived from circulating cells be used to obtain insights on liver disease status?  
Bani Mukhopadhyay (USA)

05:00 - 05:15 pm  
What can we learn from cardiopoietic therapy approaches to resolve cirrhosis?  
Scott Friedman (USA)

05:15 - 05:30 pm  
Application of single cell seq in understanding NASH and liver fibrosis.  
Thomas Baumert (France)

05:30 - 06:00 pm  
Discussion

06:00 pm  
**POSTER AWARD**

**FRIDAY, JULY 10, 2020**

07:45 - 08:00 am  
**WELCOME DESK OPENING**

08:00 - 09:15 am  
**SESSION 5 • INNOVATIONS IN TRIAL DESIGN AND OUTCOMES ASSESSMENT**
Chairs: Laurent Castera (France) and Jean-François Dufour (Switzerland)

08:00 - 08:15 am  
Assessment of causality in suspected DILI.  
Alexander Gerbes (Germany)

08:15 - 08:30 am  
Innovations in imaging to assess metabolic stress, inflammation and function of the liver.  
Lars Johansson (Sweden)

08:30 - 08:45 am  
Hierarchical endpoints for NASH.  
Dianne Finkelstein, (USA)

08:45 - 09:15 am  
Discussion

09:15 - 09:45 am  
**COFFEE BREAK**
09:45 - 11:30 am  
**SESSION 6 • ADVANCES IN NASH PHARMACOLOGY**

Chairs: Arun Sanyal (USA) and Michael Trauner (Austria)

- 09:45 - 10:00 am  
  *The FGF axis in NASH. Comparison of FGF21 and FGF19 analogs.*
  David Mangelsdorf (USA)

- 10:00 - 10:15 am  
  *The impact of SGLT2 inhibition on metabolic homeostasis.*
  Michael Roden (Germany)

- 10:15 - 10:30 am  
  *Small molecule therapy.*
  Manuel Romero Gómez (Spain)

- 11:00 - 11:30 am  
  *Debate: The best approach to NASH is to treat the root cause rather than a pure anti-fibrotic strategy.*
  Moderators: Scott Friedman (USA) and Lawrence Serfaty (France)
  For: Philip Newsome (United Kingdom)
  Against: Fabio Marra (Italy)

- 11:00 - 11:30 am  
  Discussion

11:30 - 12:00 pm  
**SPECIAL LECTURE**

Chair: Philippe Mathurin (France)

Redefining the metabolic syndrome as a systemic steatosis-inflammation-fibrosis syndrome.
Arun Sanyal (USA)

12:00 - 2:20 pm  
**LUNCH BREAKOUT SESSION**

**GROUP 1:** Industry symposium

**GROUP 2:** Review of recent clinical trials of NASH.
Raluca Pais (France) and Mary Rinella (USA)

**GROUP 3:** Endoscopic bariatric and metabolic therapies.
Jacques Devière (Belgium) and Jean-Michel Gonzalez (France)

02:00 - 04:00 pm  
**SESSION 7 • REGULATORY UPDATE**

Chair: Lawrence Serfaty (France)
Veronica Miller (USA, Liver Forum)

02:00 - 04:00 pm  
**SESSION 8 • INDUSTRY CORNER**

Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)

04:00 pm  
**Concluding remarks**
Arun Sanyal (USA)
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANSTEE Quentin</td>
<td>MATHURIN Philippe</td>
</tr>
<tr>
<td>BAUMERT Thomas</td>
<td>MILLER Veronica</td>
</tr>
<tr>
<td>BedoSSa Pierre</td>
<td>MUKHOPADHYAY Bani</td>
</tr>
<tr>
<td>CASTERA Laurent</td>
<td>NEWSOME Philip</td>
</tr>
<tr>
<td>DEVIERE Jacques</td>
<td>PAIS Raluca</td>
</tr>
<tr>
<td>DUFOUR Jean-François</td>
<td>REGEV Arie</td>
</tr>
<tr>
<td>FINKELSTEIN Dianne</td>
<td>RODEN Michael</td>
</tr>
<tr>
<td>FRIED Michael</td>
<td>ROMEO Stefano</td>
</tr>
<tr>
<td>FRIEDMAN Scott</td>
<td>ROMERO-GÓMEZ Manuel</td>
</tr>
<tr>
<td>GERBES Alexander</td>
<td>RINELLA Mary</td>
</tr>
<tr>
<td>GONZALEZ Jean-Michel</td>
<td>SANYAL Arun</td>
</tr>
<tr>
<td>JOHANSSON Lars</td>
<td>SERFATY Lawrence</td>
</tr>
<tr>
<td>MAGRE Jocelyne</td>
<td>SIDDIQUI Mohammad Shadab</td>
</tr>
<tr>
<td>MANGELSDORF David</td>
<td>STAELS Bart</td>
</tr>
<tr>
<td>MARRA Fabio</td>
<td>TACHE Franck</td>
</tr>
<tr>
<td>MARCELLIN Patrick</td>
<td>TRAUNER Michael</td>
</tr>
<tr>
<td></td>
<td>TSOCHATZIS Emmanuel</td>
</tr>
<tr>
<td></td>
<td>VAN GAAL Luc</td>
</tr>
</tbody>
</table>
July 9 & 10, 2020, Paris

INSTITUT PASTEUR
28 Rue du Docteur Roux
75015 PARIS • FRANCE

Congress Secretariat
TAMING HEALTHCARE
24 rue des Bons Raisins
92150 Suresnes - France
+33 1 87 15 30 30

Contact:
contact@paris-nash.org

www.paris-nash.org